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ABSTRACT OF THE DISSERTATION 
Brain Insulin Action Regulates Hypothalamic Glucose Sensing and the 
Counterregulatory Response to Hypoglycemia 
by 
Kelly Annette Diggs-Andrews 
Doctor of Philosophy in Biology and Biomedical Sciences 
(Molecular Cell Biology) 
Washington University in St. Louis, 2010 
Dr. Simon J. Fisher, Chairperson 
 
The brain is the primary organ that senses blood glucose levels and initiates a stress 
response when blood glucose levels are too low (hypoglycemia).  Insulin-dependent 
people with Type 1 diabetes (T1DM) have an impaired ability to sense hypoglycemia and 
an impaired ability to activate this counterregulatory response (CRR) to hypoglycemia.  
As a result, T1DM are at a greater risk of experiencing insulin induced severe 
hypoglycemic episodes, which can result in seizures, brain damage, or even death.  Since 
hypoglycemia is a major barrier that limits intensive blood glucose control, important 
research initiatives are needed to prevent or reduce the burden of hypoglycemia for 
people with Type 1 diabetes, specifically by defining the "mechanisms and modulators" 
of brain glucose sensing.  The experiments in this thesis were designed to investigate the 
role and mechanism by which insulin may regulate brain glucose sensing.  Recent 
evidence suggests that insulin acts in the brain to regulate glucose homeostasis, central 
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nervous system (CNS) glucose sensing, and the CRR to hypoglycemia, but the site and 
method of CNS insulin action are still unknown.  This study 1) investigated whether 
insulin acts on hypothalamic neurons to regulate brain glucose sensing and 2) ascertained 
how insulin regulates glucose sensing by evaluating its effects on key glucose sensors 
and CNS glucose uptake.  Taking advantage of a genetic mouse model that chronically 
lacks CNS insulin action (the neuronal insulin receptor knockout “NIRKO” mouse), this 
report assessed whether CNS insulin signaling regulates the brain's ability to detect and 
respond to hypoglycemia by analyzing glucose counterregulation and neuronal activation 
in response to hypoglycemia.  Further, to clarify a mechanism of CNS insulin action, this 
study assessed whether insulin regulates key glucose sensors and/or CNS glucose uptake 
by examining the expression patterns of key glucose sensing proteins, including glucose 
transporters (GLUTs) and glucokinase (GK), and measuring regional brain glucose 
utilization.  Understanding how the brain regulates the counterregulatory response to 
hypoglycemia is critical to devise therapies to combat severe hypoglycemia in diabetic 
patients.  Overall, this thesis provides new insights into insulin's role in the brain to 
regulate CNS glucose sensing and the counterregulatory response to hypoglycemia. 
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THESIS INTRODUCTION 
Diabetes 
Glucose homeostatic mechanisms exist to maintain stable blood glucose levels.  When 
mechanisms controlling whole-body glucose homeostasis are dysregulated, 
pathophysiologic consequences, including diabetes, can occur (1;2).  Diabetes is a 
classification of metabolic diseases characterized by chronically elevated blood glucose 
levels (hyperglycemia).  Diabetes develops predominately from impairments in the action 
and/or production of the key regulatory hormone, insulin.  Insulin is an endocrine 
hormone secreted by the pancreas that stimulates glucose uptake into peripheral tissues 
and suppresses liver glucose production in order to reduce elevated blood glucose levels.  
For patients with type 1 diabetes (T1DM), autoimmune destruction of the insulin-
producing pancreatic β-cells results in insulin deficiency.  In type 2 diabetic patients 
(T2DM), insulin-responsive tissues (i.e. muscle and fat) become insensitive to the actions 
of endogenous insulin, causing insulin resistance.  Overt diabetes develops in type 2 
diabetes when pancreatic β-cells fail to secrete enough insulin to compensate for the 
degree of insulin resistance.  For both type 1 and type 2 diabetic patients, the lack of 
appropriate insulin release and/or signaling results in chronically elevated blood glucose 
levels. 
 
Due to hyperglycemia, patients with diabetes often suffer from a number of macro- and 
microvascular complications, including retinopathy, hypertension, renal failure, 
cardiovascular disease, etc., leading to increased morbidity/mortality and overall reducing 
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quality of life (3-5).  Diabetes is a major health problem in the United States, with nearly 
25 million citizens (10% of the total population) affected with diabetes (6).  Diabetes is a 
chronic debilitating disease requiring years of treatment.  As a result, diabetes causes an 
undue burden on the United States healthcare system and costs nearly $200 billion 
annually to treat cases of diabetes (6).  This crisis is projected to worsen over the next 40 
years as a recent Center for Disease Control and Prevention (CDC) study reported that 
the number of Americans afflicted with diabetes may triple by 2050 (7).   
 
To limit major complications associated with diabetes, diabetic patients are often 
prescribed a drug regimen, along with lifestyle modifications, to help correct 
hyperglycemia and to improve insulin sensitivity.  Insulin secretagogues and sensitizers, 
including sulfonylureas and thiazolidinediones, are commonly used oral medications that 
stimulate endogenous insulin release or enhance insulin action on peripheral tissues.  All 
patients with type 1 and many patients with advanced type 2 diabetes require exogenous 
insulin therapy to correct glucose levels.  An unfortunate consequence and major 
complication of insulin therapy is the increased risk of dropping glucose levels too low, 
causing hypoglycemia. 
 
Hypoglycemia  
As an obligate glucose consumer, the brain is critically dependent on glucose supply for 
normal function.  Therefore, maintaining blood glucose levels within a tight 
physiological range is essential to achieve whole-body glucose homeostasis.  For patients 
with diabetes, many of the glucose lowering drugs (including insulin) used to treat 
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hyperglycemia can reduce blood glucose levels below the physiological range and induce 
a state of hypoglycemia (low blood sugar).  In response to hypoglycemia, the brain 
coordinates a hierarchical stress (counterregulatory) response to rapidly restore normal 
blood sugar levels (Figure 1).  The normal counterregulatory response (CRR) initiates a 
primary systemic hormone response, involving a reduction in endogenous insulin 
secretion from the pancreatic β-cells and an increase in glucagon secretion from the 
pancreatic α-cells.  The counterregulatory stress response also involves activation of 
critically important glucose sensing areas in the hypothalamus, which respond to 
hypoglycemia by activating sympathetic efferent signals to the adrenal medulla to rapidly 
release epinephrine (8-11).  The hypothalamic release of corticotrophin releasing 
hormone (CRH) mediates release of adrenocorticotrophin hormone (ACTH) systemically 
to trigger cortisol release from the adrenal cortex, which may be an important 
counterregulatory response in the setting of more prolonged hypoglycemia.  There is also 
the development of autonomic symptoms which are mediated by the release of 
catecholamines (norepinephrine and epinephrine).  These symptoms include tremor, 
anxiety, and palpitations which occur as a result of norepinephrine and epinephrine being 
released from sympathetic postganglionic neurons and/or the adrenal medulla and 
sweating, hunger, and paresthesias which occur as a result of the release of acetylcholine 
from sympathetic postganglionic neurons.  The awareness of these autonomic symptoms 
alert the hypoglycemic individual to take corrective action (i.e., consume sugar) to 
correct the hypoglycemic episode.  When blood glucose levels drop below 50mg/dL, 
neuroglycopenic symptoms develop (impaired cognition, weakness, confusion, lethargy, 
coma and death). 
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Many patients with diabetes experience frequent episodes of severe, temporarily 
disabling hypoglycemia (12;13).  Severe hypoglycemia is associated with several 
detrimental symptoms, including seizures, coma, brain damage, and even death (13).  
Hypoglycemia is caused by relative insulin excess and the condition is made worse in the 
setting of impaired counterregulation.  There are many reasons why patients with both 
Type 1 and long-standing Type 2 diabetes have defective counterregulatory responses to 
hypoglycemia and are therefore susceptible to more frequent and more severe episodes of 
hypoglycemia.  Several components of the counterregulatory response (specifically the 
suppression of endogenous insulin secretion and stimulation of glucagon and 
catecholamine release) are blunted or completely absent in diabetic patients (14-17).  
Accompanied by impaired counterregulation, intensive insulin therapy markedly 
increases the risk of severe hypoglycemia in type 1 diabetic patients (3).  As a result, 
hypoglycemia stands as the rate-limiting step for tight glycemic management in diabetic 
patients (18).  This barrier of hypoglycemia prevents people with diabetes from achieving 
the known benefits associated with intensive blood sugar control.  To improve glycemic 
management of diabetic patients, a better understand of hypoglycemic counterregulation 
is needed.  By understanding how the brain regulates the counterregulatory response to 
hypoglycemia and identifying key glucose sensing systems in the central nervous system, 
it will allow for the appropriate identification of clinical therapeutic strategies to combat 
severe hypoglycemia in patients with diabetes.  
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Insulin in the CNS  
Once considered insulin-insensitive, insulin action in the brain has become an area of 
intense investigation.  Insulin and insulin receptors have been localized throughout the 
central nervous system (CNS) (19-23) and act diversely to affect feeding, body weight, 
reproduction, and neurotransmission (24-31).  More importantly, CNS insulin action has 
been implicated as a major contributor to the counterregulatory response to hypoglycemia 
(32;33).  Insulin has been shown to cross the blood-brain barrier to directly activate the 
autonomic nervous system (34-38).  Furthermore, in studies where insulin was selectively 
directed to the brains of hypoglycemic dogs, the counterregulatory response was greatly 
augmented (39;40).  Conversely, genetic ablation of CNS insulin action (as seen in the 
NIRKO model) resulted in impaired counterregulation (41).  Also, insulin treatment has 
been shown to increase the action potential frequency of glucose responsive neurons 
during hypoglycemia (42).  These studies suggest that insulin operates within the CNS to 
regulate hypoglycemic counterregulation.   
 
It is unclear how insulin modulates the counterregulatory response in the brain, but this 
thesis approaches deciphering the mechanism by analyzing similarities between 
mechanisms of insulin action in peripheral glucose sensors.  Most interestingly, insulin 
receptors demonstrate overlapping expression with key glucose sensing proteins in key 
regions of the hypothalamus, specifically glucose transporters (GLUTs) and glucokinase 
(GK).  As a result, it is postulated that brain insulin action may mediate its effects on 
glucose sensing via regulation of glucose transporters (GLUTs) and/or glucokinase (GK).  
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This thesis analyzes insulin’s influence over these proteins in order to gain a better 
understanding of insulin’s role in CNS glucose sensing. 
 
Central Nervous System (CNS) Glucose Sensing 
In order to detect slight fluctuations in glucose levels, the body is equipped with 
numerous glucose sensors located throughout the body, including the gut, portal vein, 
pancreas, and brain (43-47).  Due to its high glucose demands, many studies have 
confirmed that the brain serves as the primary glucose sensor and the hypothalamus 
functions as the integrative center of glucose sensing (8-11).  Within the hypothalamus, 
glucose sensing predominates in discrete regions, namely the ventromedial hypothalamus 
(VMH), arcuate nucleus (ARC), and paraventricular nucleus (PVN).  Of which, the 
region most studied is the VMH.  Several studies abolishing VMH function have 
demonstrated its role in CNS glucose sensing.  Specifically, creating lesions or chemical 
destruction of the VMH deregulated peripheral glucose homeostasis (11;48-50).   
 
While all neurons metabolize glucose as a fuel source, a set of critically important 
neurons within the VMH and brain stem sense and respond to changes in blood sugar.   
By coupling their neuronal activity (i.e., firing rate) in response to their metabolism of 
glucose, these specialized neurons have been classified as “glucose sensing” neurons and 
not merely as “glucose using” neurons.  These glucose sensing neurons are categorized as 
either glucose-excited neurons (GE), which increase their firing rate when extracellular 
glucose concentrations are elevated or glucose-inhibited neurons (GI), which are 
activated by decreases in extracellular glucose concentration or by cellular glucoprivation 
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(50-52).  Both neuronal populations are widely distributed throughout the brain, but 
display distinct enrichment in hypothalamic and hindbrain regions classically associated 
with neuroendocrine regulation, energy homeostasis, and nutrient metabolism.  
 
The mechanism of CNS glucose sensing is not clearly defined but appears to be 
dependent on the metabolism of glucose within key glucose sensing neurons (GSN).  
Reports indicate that GSN located in the ventromedial hypothalamus (VMH) contain 
critical glucose sensors that mediate many of the counterregulatory responses to 
hypoglycemia (8-11).  To better understand CNS glucosensing, researchers have drawn 
clues from more widely studied glucose sensing mechanisms, including the classic 
glucose sensing system—pancreatic β-cell (Figure 2).  Glucose sensing in the β-cell is a 
dose-dependent process that joins elevations in glucose uptake/metabolism to insulin 
release.  Analogous to the β-cell, GE neurons enhance their firing activities when 
extracellular glucose rises.  Furthermore, the existences of key β-cell glucose sensing 
proteins, including glucose transporters (GLUTs), glucokinase (GK), and ATP-sensitive 
K+ channels (KATP), have been reported in hypothalamic nuclei (44;52-54).  Therefore, it 
is speculated that these proteins may have a broadened role to include CNS glucose 
sensing.  The mechanism of glucose sensing in GI neurons is even less characterized.  GI 
neurons contain many of the same glucose sensing proteins as GE neurons, including 
glucose transporters and glucokinase (55).  However, the mechanism linking increases in 
glucose concentrations to suppression of neuronal firing may involve additional players, 
including regulation of the sodium-potassium channel activity and/or ATP-sensitive 
chloride channels, to facilitate glucose-mediated silencing (55-57).  In addition to 
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regulating electrical activity, glucosensing neurons may also mediate their effects through 
nutrient sensors or the release of neurotransmitters in the brain, including GABA 
(inhibitory) and glutamate (excitatory) (58;59). 
 
Glucose sensing neurons also play an important role in the detection of hypoglycemia 
and the initiation of the counterregulatory response; therefore changing any key glucose 
sensor may result in altered hypothalamic glucose sensing and impaired initiation of the 
counterregulatory response.  As a consequence, these key glucose sensing proteins, 
among other hypothalamic nutrient sensors, may serve as therapeutic targets to combat 
hypoglycemia. 
 
Facilitative Glucose Transporters (GLUTs) 
Glucose transport is a fundamentally important process in energy metabolism.  The body 
needs to maintain a relatively constant supply of blood glucose to sustain brain 
metabolism and to maintain transport of glucose to peripheral tissues for utilization and 
storage (60). Facilitative glucose transporters (GLUTs) support the passive influx of 
glucose into cells.  Several GLUTs have been identified in the brain (61;62).  Of these, 
GLUT1 and GLUT3 are the predominate isoforms expressed in the brain (63).  Although 
found in lower quantities, GLUT2 is expressed in key glucose sensing regions (64;65).  
Similar to its role in β-cell glucosensing, mounting evidence suggests that GLUT2 may 
be involved in hypothalamic glucosensing (66;67).  GLUT4, the insulin-responsive 
glucose transporter, is expressed along with the insulin receptor in many important brain 
regions involved in glucose sensing (68;69).  
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Glucokinase (GK) 
Glucokinase (GK) is a hexokinase that regulates glucose phosphorylation and metabolism 
in the β-cell and liver (44;55).  Similar to its peripheral functions, GK may also play a 
role in the hypothalamus to mediate glucose sensing (70).  Demonstrated by both in-situ 
hybridization and RT-PCR, glucokinase is expressed in several hypothalamic regions 
(55;71).  Further, modulating hypothalamic GK activity has been shown to regulate the 
counterregulatory response to hypoglycemia.  Specifically, studies were performed to 
inhibit hypothalamic GK activity by injecting the glucokinase inhibitor alloxan or an 
adenovirus expressing a GK short hairpin RNA (to chronically reduce GK hypothalamic 
expression) into the ventricle that bathes the hypothalamus (intracerebroventricular—
ICV).  Results of these studies show that GK inhibition selectively enhanced the 
epinephrine response to hypoglycemia (71).  Conversely, enhancing GK activity with a 
glucokinase activator (Compound A) markedly suppressed the counterregulatory 
response (71).  
 
Ion channels: ATP-sensitive K+ (KATP) and ATP-sensitive Cl- channels 
ATP-sensitive K+ channels (KATP) may provide a link between glucose metabolism and 
electrical activity in glucose sensing neurons.  Several KATP channel subunits (Kir6.2, 
SUR1, and SUR2) have been localized in key glucosensing regions of the hypothalamus 
(72;73).  The involvement of the KATP channel in central glucose sensing and 
counterregulation has been also shown by several in vivo studies.  Either ICV or direct 
VMH injection of the channel inhibitor glibenclamide blocks the counterregulatory 
response to acute hypoglycemia or anti-metabolite-induced glucopenia (74).  KATP 
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channel inactivation (via Kir6.2 gene knockout) also leads to an impaired 
counterregulatory response to hypoglycemia.  Further, KATP inactivity correlates to 
suppressed glucose-regulated firing activity of VMH neurons (75).  In contrast, activation 
of ATP-sensitive K+ channels in the VMH with channel opener diazoxide amplifies 
counterregulatory hormone responses to hypoglycemia in normal and recurrently 
hypoglycemic rats (76). 
 
ATP-sensitive Cl- channels are postulated to play an important role in the electrical 
activity of GI neurons.  In response to decreased glucose levels, neuronal ATP levels are 
reduced, the Cl− channel becomes inactivated, and the GI neuron becomes depolarized.  
This form of ATP-activated Cl− conductance has been demonstrated in key glucose 
sensing systems, namely the pancreatic islet cells (77). Further, an example of these Cl- 
channels, cystic fibrosis transmembrane regulator (CFTR), CFTR mRNA and protein has 
been localized in human and rat hypothalamus (78-80), suggesting a role of these 
channels in central glucose sensing mechanisms. 
 
Other Glucose Sensing Players: AMPK and Neurotransmitters 
AMP-activated protein kinase (AMPK) is an important nutrient sensor present in the 
brain.  When nutrient supplies are low, there is an increase in cellular AMP, which leads 
to allosteric activation of AMPK.  AMPK activity stimulates catabolic pathways and 
suppresses anabolic pathways to restore energy homeostasis.  In the hypothalamus, 
AMPK activity is increased in response to insulin-induced hypoglycemia and reduced by 
peripheral or ICV glucose infusion (81;82).  AMPK may also regulate the 
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counterregulatory response to hypoglycemia.  Enhancing VMH-AMPK activity with an 
activator, AICAR, markedly increases endogenous glucose production during a 
hypoglycemic clamp and improved the counterregulatory response in animals with 
defective counterregulation (83;84).  Conversely, blocking hypothalamic AMPK with 
compound C, expressing a dominant negative form of AMPK, or reducing hypothalamic 
AMPK expression via RNA interference strongly reduced counterregulation to insulin-
induced hypoglycemia (83).  
 
Two major classes of neurotransmitters in the brain, GABA (inhibitory) and glutamate 
(excitatory), have been postulated to play a role in CNS glucose sensing (58;59).  
Blocking GABA receptors in the VMH stimulates counterregulatory response to 
hypoglycemia (59;85) while blocking glutamate release in the VMH impairs the 
counterregulatory response to hypoglycemia (58).  These studies suggest that 
neurotransmission in VMH neurons provide an unappreciated role to the CNS glucose 
sensing mechanism.  Further, modulation of neurotransmission in the brain may act as an 
additional clinical target to prevent hypoglycemia.  
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Figure 1. Glucose sensing and the physiological response to hypoglycemia. 
In the normal response to hypoglycemia, the brain (esp. the hypothalamus) coordinates 
and triggers a stress response to restore euglycemia. This process includes stimulating the 
HPA axis and sympathetic nervous system to increase production of key 
counterregulatory hormones. Cortisol (via ACTH release) and epinephrine secretions 
arise from the adrenal cortex and medulla, respectively. The sympathetic nervous system 
also increases norepinephrine and acetylcholine release, to stimulate observable 
symptoms of hypoglycemia. At the level of the pancreas, endogenous insulin secretion 
from the β-cell is suppressed while glucagon release from the α-cell is elevated. This 
processes work in unison to normalize blood glucose levels. 
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Figure 2. Proposed mechanism of glucose sensing in glucose sensing neurons. 
During euglycemia or hyperglycemia, the proposed glucose-excited (GE) glucose sensing 
mechanism requires glucose uptake via glucose transporters (GLUTs), glucose 
phosphorylation by the rate-limiting enzyme glucokinase (GK), and subsequent 
metabolism of glucose to increase the intracellular ATP-to-ADP ratio.  Following glucose 
metabolism, closure of ATP-sensitive K+ channels, membrane depolarization, and 
neuronal firing occurs.  When glucose levels fall, as seen during hypoglycemia, neuronal 
activity is decreased in GE neurons and glucose-inhibited (GI) neurons are activated.  
Similar to GE neurons, glucose sensing in GI is proposed to involve GLUTs, GK, and 
altered ATP-to-ADP ratio.  Glucose sensing in the GI is speculated to also involve ATP-
sensitive Cl- channels and activation of the fuel sensor, AMPK, leading to initiation of the 
counterregulatory response to hypoglycemia.  ∆Vm: change in membrane potential, 
membrane depolarization. 
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CHAPTER 1.  HYPOGLYCEMIC COUNTERREGULATION AND NEURONAL 
ACTIVATION IN A MODEL OF CHRONIC CENTRAL NERVOUS SYSTEM 
(CNS) INSULIN RESISTANCE 
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ABSTRACT 
An impaired ability to sense and appropriately respond to insulin-induced hypoglycemia 
is a common and serious complication faced by insulin-treated diabetic patients.  This 
study tests the hypothesis that insulin acts directly in the brain to regulate critical glucose 
sensing neurons in the hypothalamus to mediate the counterregulatory response to 
hypoglycemia.  To delineate insulin actions in the brain, neuron-specific insulin receptor 
knockout (NIRKO) mice and littermate controls were subjected to graded hypoglycemic 
(100, 70, 50, and 30 mg/dL) hyperinsulinemic (20 mU.kg-1.min-1) clamps.  Subsequently, 
counterregulatory responses and hypothalamic neuronal activation (with transcriptional 
marker c-fos) were measured.  Additionally, electrophysiological activity of individual 
glucose-inhibited (GI) neurons was measured.  NIRKO mice revealed a glycemia-
dependent impairment in the sympathoadrenal response to hypoglycemia and 
demonstrated markedly reduced (70%) hypothalamic c-fos activation in response to 
hypoglycemia.  Further, GI neurons in the ventromedial hypothalamus of NIRKO mice 
displayed significantly blunted glucose responsiveness to decreases in extracellular 
glucose from 2.5 to 0.5mM (membrane potential and input resistance responses were 
blunted 66% and 80%, respectively).  We conclude that insulin acts in the brain to 
regulate the counterregulatory response to hypoglycemia by directly altering glucose-
mediated activation of hypothalamic neurons and shifting the glycemic levels necessary 
to elicit a normal sympathoadrenal response to hypoglycemia.   
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INTRODUCTION 
Intensive insulin therapy markedly increases the risk of severe hypoglycemia in people 
with type 1 (86) and type 2 (4) diabetes.  Thus, hypoglycemia is the rate-limiting step for 
tight glycemic management in diabetic patients.  In response to hypoglycemia, glucose 
sensors in the central and peripheral nervous system coordinate efferent autonomic 
responses resulting in the release of key counterregulatory hormones—glucagon, 
norepinephrine, epinephrine, and cortisol.  This coordinated response stimulates hepatic 
glucose output and restricts glucose utilization in order to increase blood sugar levels.  
Patients with diabetes often have an impaired ability to sense and respond to 
hypoglycemia (12;13;87) because several components of the counterregulatory response 
have been shown to be either absent (i.e. fall in insulin, rise in glucagon) or markedly 
blunted (i.e. the sympathoadrenal response) (16;17).  
 
While hypoglycemia is caused by absolute or relative insulin excess, the role of insulin in 
regulating the counterregulatory response is unclear.  Studies have demonstrated that 
increased insulin levels may augment (32;88-90), diminish (91), or not change (33;92-94) 
the sympathoadrenal response to hypoglycemia. Given recent evidence indicating that 
insulin acts in the brain (28), some studies have investigated whether insulin’s putative 
actions in regulating the counterregulatory response might be mediated via actions in the 
central nervous system.  Again, conflicting reports suggest that insulin may act centrally 
to enhance (39-41), reduce (95;96) or not alter (97) the sympathoadrenal response to 
hypoglycemia.  In this study, the neuronal specific insulin-receptor knockout (NIRKO) 
mouse model,  which chronically lacks central nervous system (CNS) insulin signaling 
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(28;98), was used to investigate the role by which brain insulin action regulates central 
glucose sensing and the counterregulatory response to hypoglycemia.  
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MATERIALS AND METHODS 
Animals.  Mice homozygous for the floxed insulin receptor allele (IRlox-lox) were bred 
with transgenic mice that express Cre recombinase cDNA from the rat nestin promoter to 
generate (IRlox-lox:nestin-Cre+/-) nervous system specific insulin receptor knockout 
(NIRKO) mice (28). Genotypes were determined by PCR of tail DNA.  Unless otherwise 
indicated, 2-4 month old NIRKO (IRlox-lox:nestin-Cre+/-) and littermate control (Control, 
IRlox-lox:nestin-Cre-/-) mice were used for these experiments.  All mice were housed on a 
12-hour light/dark cycle and fed a standard rodent chow (Mouse Diet 9F, PMI Nutrition 
International, St. Louis, MO) ad libitum.  All procedures were in accordance with the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health 
and were approved by the Animal Studies Committee of Washington University. 
 
Hypoglycemic-hyperinsulinemic glucose clamps. Mice anesthetized with 
ketamine/xylazine (87 and 13.4 mg/kg IP) were implanted with catheters (MRE 025, 
Braintree Scientific Inc., Braintree, MA) into both the right internal jugular and the left 
carotid or femoral artery.  After a 5-7 day recovery period, hyperinsulinemic (20mU.kg-
1
.min-1) hypoglycemic clamps were performed in 5-hour fasted, awake, unrestrained, 
NIRKO and control mice (n=6-9 per group).  To create various degrees of hypoglycemic 
stress, arterial blood glucose (~2µL) was measured at ten-minute intervals as a 
continuous infusion (20 mU/kg/min) of human regular insulin (Humulin, Eli Lilly and 
Co.) in 0.1% BSA and 50% dextrose were administered. The rate of intravenous 50% 
dextrose infusion was variable and carefully adjusted to create equivalent levels of mild 
(70mg/dL), moderate (50mg/dL), and severe hypoglycemia (30mg/dL) as well as a 
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euglycemic (110mg/dL) control.  HPLC-purified [3-3H]-glucose tracer (NEN Life 
Science Products Inc., Boston, MA) was infused (10µCi bolus followed by 0.1µCi/min 
continuous infusion) for the assessment of hepatic glucose production (99).  After a 90 
minute basal period, three blood samples (10µL) at 10 minute intervals were taken for 
hepatic glucose production determination. Three blood samples were also taken during 
the last half hour of the clamp.  An additional blood sample (130µL) was obtained for 
hormonal measurements (insulin, glucagon, epinephrine, norepinephrine, and 
corticosterone) during the basal period and at the end of the clamp. Whole-body glucose 
turnover was determined during the steady state from the ratio of the [3H] glucose 
infusion rate to the measured specific activity of plasma glucose (99).  Hepatic glucose 
production (HGP) was determined by subtraction of the glucose infusion rate from the 
whole-body glucose turnover (99).   
 
Hypoglycemia-induced c-fos expression.  Awake, 5-hour fasted NIRKO (n=4) and 
littermate controls (n=6) were given a single intraperitoneal (IP) injection of high dose 
insulin (3.0-3.5U/kg) to achieve a consistent and stable hypoglycemic insult (~30mg/dL) 
for 2 hours.  Euglycemic controls (~110mg/dL, n=4 per group) were given an IP injection 
of saline.  After a 2 hour duration of hypoglycemia (or euglycemia), mice anesthetized 
with isofluorane and transcardially perfused with 0.01 M PBS (Sigma, Saint Louis, MO) 
followed by 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA).  The 
brains were immersed in 4% paraformaldehyde overnight and then cryoprotected in 30% 
sucrose.  Brain sections were then processed for c-fos immunostaining.  Free-floating 
brain sections (20-30µm) containing the paraventricular nucleus (PVN) of the 
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hypothalamus were blocked with 30% normal goat serum diluted in 0.1% Triton-
100/PBS and then incubated overnight at 4°C with c-fos antibody (1:2000, Ab-5, 
Calbiochem, San Diego, CA).  Subsequently, the sections were mounted on slides and 
processed with biotinylated goat anti-rabbit immunoglobulin G (1:200) using the Elite 
ABC kit (Vector Laboratories, Burlingame, CA). As a negative control, alternative 
sections were incubated without primary antibodies.  Anatomical landmarks were used to 
identify the paraventricular nucleus of the hypothalamus (100).  Positively stained cells 
were counted by a blinded investigator.  Four to six anatomically matched sections per 
mouse were quantified for statistical purposes. 
 
Electrophysiological studies.  Male 14-28 day old NIRKO and littermate control mice 
were anesthetized and transcardially perfused with ice-cold oxygenated perfusion.  On 
the day of the experiment, mice were anesthetized and transcardially perfused with ice-
cold oxygenated (95% O2/5% CO2) perfusion. Sections (350µm) through the 
hypothalamus were made on a vibratome (Vibroslice; Camden Instruments).  The brain 
slices were maintained at 34°C in oxygenated high-Mg2+ low-Ca2+ artificial cerebrospinal 
fluid for 30 minutes and then transferred to normal oxygenated ACSF (2.4 mmol/l CaCl2 
and 1.3 mmol/l MgCl2) for the remainder of the day.  Viable neurons were visualized and 
studied under infrared differential-interference contrast microscopy using a Leica DMLS 
microscope equipped with a 40× long working-distance water-immersion objective.  
Current-clamp recordings (standard whole-cell recording configuration) from neurons in 
the VMH were made using an Axopatch 1D amplifier (Axon Instruments, Foster City, 
CA) as previously described (101;102).  During recording, brain slices were perfused at 
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10mL/min with normal oxygenated ACSF.  Borosilicate pipettes (1–3 MΩ; Sutter 
Instruments, Novato, CA) were filled with an intracellular solution containing (in 
mmol/l): 128 K-gluconate, 10 KCl, 4 KOH, 10 HEPES, 4 MgCl2, 0.5 CaCl2, 5 EGTA, 
and 2 Na2ATP; pH 7.2.  Osmolarity was adjusted to 290–300 mOsm with sucrose.  Input 
resistance was calculated from the change in membrane potential in response to small 
500-msec hyperpolarizing pulses (−10 to −20pA) given every 3 seconds.  Briefly, 
hyperpolarizing current pulses varying from −10 to −120 pA were applied at 10- or 20-
pA increments.  At each increment, four pulses were applied.  The duration of each pulse 
was 500 ms, and pulses were applied every 3 seconds.  The membrane potential response 
during the last 5 ms of each pulse (when dV/dt = 0) was measured, and the average of the 
four pulses at each amplitude was calculated.  The membrane potential response was 
measured only after the membrane response to altered extracellular glucose had 
stabilized, and this value was compared with controls that were measured immediately 
before changing extracellular glucose.  Individual glucose inhibited (GI) neurons were 
identified as those neurons that increased their action potential frequency, membrane 
potential, and input resistance with decreases in extracellular glucose from 2.5 to 0.1mM. 
 
Plasma Assays.  Blood glucose was measured by a glucometer (Becton, Dickinson and 
Company, Franklin Lakes, NJ) while plasma glucose was assayed by the glucose oxidase 
method and a spectrophotometer (BioTek Instruments, Inc., Winooski, VT).  
Radioimmunoassays were performed for glucagon (LINCO Research, Inc., St. Charles, 
MO) and corticosterone (ICN Biomedicals, Inc., Costa Mesa, CA). Insulin was assayed 
by enzyme-linked immunosorbent assay (ELISA) (Chrystal Chem. Inc., Downers Grove 
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IL). Plasma epinephrine and norepinephrine were measured with a single isotope 
derivative (radioenzymatic) method (103). 
 
Statistics.  All values are presented as the mean ± standard error of the mean (SEM).  
Statistical significance was set at p<0.05, as determined by Student’s t test. 
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RESULTS 
Brain Insulin Action is Necessary for Full Sympathoadrenal Response to Hypoglycemia 
To characterize the counterregulatory response to hypoglycemia in NIRKO mice, a series 
of hyperinsulinemic glucose clamps were performed.  Blood glucose was clamped at 110, 
70, 50 and 30mg/dL in control and NIRKO mice to induce various degrees of 
hypoglycemia (mild=70mg/dL, moderate=50mg/dL, and severe hypoglycemia=30mg/dL) 
or no hypoglycemia (euglycemic clamp=110mg/dL) (Figure 3).  In response to insulin 
infusion, plasma insulin levels were similarly elevated in NIRKO and control mice 
(Figure 4).  Severe hypoglycemia (30mg/dL) resulted in a 6-fold increase in glucagon 
levels and ~60% increase in corticosterone levels, but these increases were similar in both 
groups (Figures 4 and 5).  Norepinephrine levels trended lower in NIRKO mice during 
moderate (50mg/dL) and severe (30mg/dL) hypoglycemia, but the difference did not 
reach significance (Figure 5). 
 
In response to high dose insulin (20mU.kg-1.min-1), hepatic glucose production was 
completely inhibited during the hyperinsulinemic clamp at glycemic levels of 100, 70, 
and 50mg/dL.  During severe hypoglycemia (30mg/dL), hepatic glucose production rose 
significantly; however, the rise in hepatic glucose production was significantly blunted in 
NIRKO mice (Figure 6).  The epinephrine response was significantly impaired in NIRKO 
mice during moderate (50mg/dL) and severe (30mg/dL) hypoglycemia (Figure 7).  The 
epinephrine response was highly correlated to glycemia levels in both control (R2=0.76) 
and NIRKO (R2=0.75) mice.  Based on the shift in the hypoglycemia-epinephrine 
response curve (Figure 7-inset), the data was fitted to a four parameter logistic curve and 
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EC50 values were determine for control (46.5±3.6 mg/dL) and NIRKO (34.5±11.7mg/dL) 
mice.     
 
Absent CNS Insulin Action Impairs Hypothalamic Neuronal Activation to Hypoglycemia 
In order to assess the brain’s response to hypoglycemia, c-fos-based functional mapping 
was used to demonstrate activated neurons and functional circuits that respond to 
hypoglycemic stress (104).  Euglycemic (~110mg/dL) controls displayed low c-fos 
expression in the hypothalamus.  In response to insulin-induced hypoglycemia 
(31.5±3.1mg/dL), both NIRKO and control mice markedly increased c-fos expression 
within the paraventricular nucleus (PVN) of the hypothalamus.  However, NIRKO 
animals showed a 3-fold impairment in c-fos activation as compared to controls (Control: 
99±16 vs. NIRKO: 31±5, p<0.01) (Figure 8). 
 
Intact Neuronal Activation and Physiological Response to Extreme Glucose Deprivation 
To determine whether NIRKO mice displayed an absolute impairment in their ability to 
respond to hypoglycemic insults, NIRKO mice were subjected to extreme glucose 
deprivation (blood glucose level below 30mg/dL) to evaluate their ability to fully 
stimulate a sympathoadrenal response and/or activate neurons in the PVN.  Similar to the 
severe hypoglycemic insult, both NIRKO and control mice significantly stimulated 
neuronal activity as well as catecholamine responses to extreme glucose deprivation.  
However, when glucose levels were kept below 30mg/dL, NIRKO mice elevated c-fos 
expression and catecholamine levels similar to those seen in control mice (Figure 9). 
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Impaired Glucose Sensing in Individual Glucose-Inhibited Neurons 
Whole-cell current clamp recordings were performed to evaluate the glucose sensitivity 
of individual glucose-inhibited (GI) neurons in the ventromedial hypothalamus (VMH) 
(Figure 10).  As expected for VMH GI neurons bathed in sufficient 2.5mM glucose, 
action potentials in this basal state were absent in recordings from both control and 
NIRKO mice.  There were also no group differences in membrane potential (MP) or 
input resistance (IR) in 2.5mM glucose (Control: MP -57±4 mV, IR 1209±272 MΩ; 
NIRKO: MP -59±3 mV, IR 1016±162 MΩ).  Further, no group differences were 
observed in GI neurons in response to a maximal glucose decrease from 2.5 to 0.1mM.  
In contrast, GI neurons in NIRKO mice had a significantly impaired change in membrane 
potential and input resistance (66% and 80% impairment, respectively) in response to a 
glucose decrease from 2.5 to 0.5mM (Figure 11).  
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Figure 4.  Pancreatic hormone levels during graded hyperinsulinemic glucose 
clamps.  Results are shown for NIRKO (closed bars) and control (open bars) mice (n=6-8 
mice per group).  Top:  By experimental design, insulin levels rose markedly, and 
similarly between groups during the hyperinsulinemic clamps.  Bottom:  Glucagon levels 
in both treatment groups rose significantly above basal levels (p<0.05) during moderate 
and severe hypoglycemia but similarly between treatment groups.  
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Figure 5.  Corticosterone and norepinephrine levels during graded hyperinsulinemic 
glucose clamps.  Results are shown for NIRKO (closed bars) and control (open bars) 
mice (n=6-8 mice per group).  Top:  Corticosterone levels in both treatment groups rose 
significantly above basal levels (p<0.05) during moderate and severe hypoglycemia but 
similarly between treatment groups. Bottom:  Norepinephrine levels in both treatment 
groups rose significantly higher from the basal period during moderate and severe 
hypoglycemia but there was no difference between NIRKO and control responses. 
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Figure 6.  Hepatic glucose production during graded hyperinsulinemic glucose 
clamps.  Results are shown for NIRKO (closed bars) and control (open bars) mice (n=6-8 
mice per group).  Hepatic glucose production (HGP) before and during the 
hyperinsulinemic clamps was determined by tracer dilution methodology.  Hepatic 
glucose production (HGP), in the basal period prior to insulin infusion, was the same in 
control and NIRKO mice.  During the hyperinsulinemic glucose clamps at mild and 
moderate hypoglycemia, HGP was suppressed. In spite of the hyperinsulinemia, during 
severe hypoglycemia (30mg/dL), HGP rose significantly, but remained lower in NIRKO 
as compared to control mice. (*p<0.05) 
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Figure 7.  Adrenomedullary response in a series of hyperinsulinemic glucose clamps.  
Results are shown for NIRKO (closed bars) and control (open bars) mice (n=6-8 mice per 
group).  The epinephrine response was significantly impaired in NIRKO mice during 
moderate (50mg/dL) and severe (30mg/dL) hypoglycemia.  The inset picture 
demonstrates a shift in the hypoglycemia dose-response curve by the solid (controls) 
versus dashed (NIRKO) line.  (*p<0.05 vs. control) 
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Figure 8.  Blunted neuronal activation in response to hypoglycemia seen in NIRKO 
hypothalamus.  Top:  Representative images of matched hypothalamic sections 
highlighting c-fos staining in the paraventricular nucleus (PVN) in NIRKO (right image) 
and littermate controls (left image) after a 2 hour hypoglycemic insult.  Bottom:  
Quantification of c-fos positive cells stimulated during euglycemia (n=4 mice per group) 
and matched hypoglycemia in NIRKO (n=4, closed bars) and littermate control (n=6, 
open bars) mice (left).  Blood glucose levels are shown for NIRKO (closed circles) and 
control (open circles) mice during the hypoglycemic insult, illustrating a well-matched, 
stable hypoglycemic insult (right). (**p<0.01 vs. control) 
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Figure 9.  Intact neuronal activation and catecholamine response to extreme glucose 
deprivation.  Results shown for NIRKO (closed bars) and littermate control (open bars) 
mice (n=3-6 per group).  Top:  Quantification of c-fos positive cells from a 2 hour 
hypoglycemic insult maintained below 30mg/dL glucose in NIRKO mice and littermate 
controls.  Bottom:  Catecholamines are robustly induced during extreme glucose 
deprivation.  By maintaining blood glucose levels below 30mg/dL, NIRKO mice are able 
to stimulate both epinephrine (left) and norepinephrine (right) levels equally to control 
mice. 
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Figure 10.  Individual glucose-inhibited neurons demonstrate impaired glucose 
responsiveness in NIRKO mice.  Representative traces from standard whole-cell current 
clamp recordings of VMH glucose-inhibited (GI) neurons from a C57 control and 
NIRKO mouse in response to decreases in extracellular glucose (G) from 2.5 mM to 0.1 
and 0.5mM. Top: In a control mouse, decreased G from 2.5 to 0.1 mM and 2.5 to 0.5 
mM resulted in membrane depolarization, increased input resistance and the appearance 
of action potentials in this GI neuron. Bottom: In a GI neuron from a NIRKO mouse, 
decreased G from 2.5 to 0.1 mM resulted in membrane depolarization, increased input 
resistance and the appearance of action potentials identifying it as a GI neuron; however, 
this effect was not observed when G decreased from 2.5 to 0.5 mM. The resting 
membrane potential in 2.5 mM G is represented by the dashed line and is noted to the 
right of each trace. The upward deflections indicate action potentials and the downward 
deflections represent the membrane response to a constant current hyperpolarizing pulse.   
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Figure 11.  Changes in membrane potential and input resistance reduced in NIRKO 
glucose-inhibited neurons.  Top:  Graphs quantifying the percentage change of 
membrane potential (left) and input resistance (right) when identifying GI neurons in 
NIRKO (n=7, closed bars) and control (n=6, open bars) mice (decreases in extracellular 
glucose (G) from 2.5 to 0.1mM G).  As noted, there is no difference between groups.  
Bottom:  In response to lowering G from 2.5 to 0.5mM G, the percentage change in 
membrane potential (left) and input resistance (right) of glucose-inhibited neurons was 
significantly lower in NIRKO compared to littermate controls. (*p<0.05, **p<0.01) 
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DISCUSSION 
Insulin’s role in regulating the counterregulatory response to hypoglycemia is an area of 
active investigation.  Insulin has been shown to increase (32;39-41;88-90), diminish 
(91;95), and not alter (33;92-94;97) the sympathoadrenal response to hypoglycemia.  In 
this study, using a model of chronic brain insulin receptor deficiency, it was 
demonstrated that insulin action in the brain, 1) regulates the glucose sensitivity of 
glucose sensing neurons in the VMH, 2) regulates hypoglycemia-induced neuronal 
activation, and 3) modulates the sympathoadrenal response to hypoglycemia by altering 
the glycemic level required to elicit appropriate sympathoadrenal responses. 
 
In these studies, a ~60% rise in corticosterone was observed in response to severe 
hypoglycemia in NIRKO and control mice (Figure 5).  Although not well characterized in 
mice, this degree of hypothalamic-pituitary-adrenal (HPA) induced increment in 
corticosterone is consistent with other groups (105-109).  Contrary to the stimulatory 
effect of insulin on the cortisol response to hypoglycemia observed in canine models 
(39;40), these studies in mice demonstrate that the absence of brain insulin action does 
not impair the HPA axis response to hypoglycemia.  
 
Reports of insulin actions in the CNS in modulating the glucagon response to 
hypoglycemia are variable, with studies demonstrating insulin to increase (39;40), 
decrease (95), or not effect (41;97) the glucagon response to hypoglycemia.  In the 
current studies, the pancreatic α-cell response to severe hypoglycemia showed a 6-fold 
increase in plasma glucagon levels that was not altered by the absence of CNS insulin 
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receptors in NIRKO mice.  Interestingly, although catecholamines stimulate the α-cell, 
the impaired catecholamine response to hypoglycemia did not diminish the full glucagon 
response in NIRKO mice (Figure 4).  These results indicate that factors other than central 
insulin action and systemic catecholamine responses (perhaps, local glycemia, intra-islet 
insulin/zinc, direct innervations, etc.) are more important mediators of the glucagon 
response to hypoglycemia.   
 
The absence of brain insulin receptors resulted in a significantly impaired epinephrine 
response in NIRKO mice during moderate (50mg/dL) and severe (30mg/dL) 
hypoglycemia.  However, the absence of brain insulin signaling did not result in total 
deficiency of hypoglycemic counterregulation.  An epinephrine response of ~1500 
pg/mL, which was achieved during moderate hypoglycemia (50mg/dL) in controls, was 
also elicited at a lower blood glucose level (30mg/dL) in NIRKO mice (Figure 7).  
Further, NIRKO mice were able to stimulate a comparable catecholamine response to 
controls when blood glucose levels were lowered well below 30mg/dL (Figure 9).  
Consistent with these findings, the shift in the hypoglycemia-epinephrine response curve 
(Figure 7-inset) indicates that in the absence of insulin signaling, NIRKO mice needed to 
reach lower glycemic levels to appropriately activate their adrenomedullary response.  
While insulin infusion suppressed hepatic glucose production during the clamps, only 
during severe hypoglycemia (30mg/dL) was the counterregulatory response of a 
sufficient magnitude to overcome the suppressive effects of insulin and significantly 
increase hepatic glucose production.  In NIRKO mice, however, the counterregulatory-
induced stimulation of hepatic glucose production was significantly blunted during severe 
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hypoglycemia (Figure 6), consistent with an impaired sympathoadrenal response.  These 
findings indicate that chronic lack of CNS insulin action alters glucose sensing and/or 
responsiveness, leading to an impaired sympathoadrenal response and an impaired ability 
to defend against iatrogenic hypoglycemia.  
 
Increased c-fos expression in the paraventricular nucleus (PVN) has been used as a 
marker of transcriptional activity in stress-related neural circuitry (104;110-112).  
Expression of c-fos was therefore measured to determine whether the impaired 
sympathoadrenal response in the NIRKO mice was related to impaired activation of 
hypothalamic sensing neurons (Figures 8 and 9).  During hypoglycemia, increased c-fos 
expression was predominantly observed in the PVN and not seen in the VMH, consistent 
with other studies (113;114).  Hypoglycemia-induced c-fos activation in the PVN may 
represent direct activation in response to hypoglycemia or indirect activation in response 
to afferent input from other areas containing glucose sensing neurons.  Thus, the impaired 
c-fos activation in the PVN of NIRKO mice in response to severe hypoglycemia could 
represent reduced glucose sensing of PVN neurons; or given the abundance of insulin 
receptors in important VMH glucose sensing neurons, an indirect reduction in afferent 
inputs from glucose sensing neurons in the VMH.  Whether this defect indicates impaired 
direct or indirect glucose sensing, the reduced c-fos activation in NIRKO mice was 
profound and consistent with other models of impaired glucose sensing and impaired 
counterregulation (112;115).   
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Whole cell current clamp recordings of spontaneous electrical activity were made in 
individual glucose-inhibited (GI) neurons to assess responses of individual glucose 
sensing neurons in the VMH.  While a direct relationship between glucose sensing 
neurons and sympathoadrenal activation has yet to be definitively established, it is 
noteworthy that the ability of VMH GI neurons to sense a fall in ambient glucose levels is 
impaired under several conditions where the sympathoadrenal response to hypoglycemia 
is also impaired (i.e. rats treated with recurrent hypoglycemia or streptozotocin-induced 
diabetes) (102;116;117).  In NIRKO mice, the observed impaired response of VMH GI 
neurons to reductions in glucose levels (Figures 10 and 11) is entirely consistent with the 
impaired neuronal (c-fos) activation (Figure 8) and the impaired sympathoadrenal 
activation during severe hypoglycemia (Figure 7).  Further, the sympathoadrenal and c-
fos findings along with the electrophysiological findings that NIRKO GI neurons respond 
normally to maximal glucose deprivation (blood glucose less than 30mg/dL and 0.1mM 
G), but show impaired responses at 0.5mM are consistent with a relative, not absolute, 
impairment in glucose sensing (Figures 9-11).  These results indicate that insulin acts 
directly in the brain to regulate the glucose sensing ability of hypothalamic GI neurons 
that are critically important and functionally linked in mediating the sympathoadrenal 
response to hypoglycemia.   
 
Of particular interest is that GI neurons of NIRKO mice have an impaired ability to 
respond to a fall in glucose even in the absence of insulin administration.  Combining 
these in vitro findings to the in vivo findings suggest that it may not solely be a failure of 
insulin to acutely activate its receptor that leads to impaired glucose sensing and altered 
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neuronal responses; but rather, we propose that the chronic lack of insulin signaling in 
NIRKO mice causes long-term adaptations in gene transcription/transduction (i.e. altered 
expression of key hypothalamic glucose sensing proteins), leading to impaired glucose 
sensing.  Alternatively, since neuronal nitric oxide (NO) production is required for GI 
neurons to sense decreased glucose (118;119) and insulin enhances NO production in 
VMH GI neurons (118), the chronic lack of insulin signaling in NIRKO mice may led to 
impaired glucose sensing by impairing nitric oxide production.  It is entirely plausible 
that the chronic actions of insulin may be mechanistically very different from the acute 
actions of insulin in regulating neuronal glucose sensing and the counterregulatory 
response to hypoglycemia.   
 
In summary, it is shown that the chronic lack of insulin receptor signaling in the central 
nervous system, 1) attenuates individual hypothalamic GI neuronal responses to low 
glucose, 2) impairs hypothalamic neuronal activation in response to hypoglycemia, and 
3) reduces the sympathoadrenal response to hypoglycemia by shifting the glycemic level 
necessary to elicit appropriate sympathoadrenal responses.  It is concluded that insulin 
acts directly in the brain to regulate both glucose sensing in hypothalamic neurons and 
the counterregulatory response to hypoglycemia.  Since insulin-treated diabetic patients 
have an impaired ability to sense and appropriately respond to insulin-induced 
hypoglycemia, the mechanisms by which insulin regulates central nervous system 
glucose sensing need to be actively investigated as research scientists endeavor to 
supplant insulin-induced hypoglycemia as the rate-limiting factor in the glycemic 
management of diabetes.  
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CHAPTER 2.  INSULIN-REGULATED GLUCOSE TRANSPORTER GLUT4 
MAY MEDIATE THE UNIQUE RESPONSE TO HYPOGLYCEMIA SEEN IN 
MICE LACKING BRAIN INSULIN ACTION 
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ABSTRACT 
Insulin acts in the brain to affect numerous physiological functions, including 
reproduction, neurotransmission, appetite, and glucose homeostasis.  Recent reports in 
the CNS insulin receptor knockout (NIRKO) mouse also indicate a significant role of 
insulin action in the brain to regulate hypoglycemic counterregulation and glucose 
sensing.  However, it is unclear whether these impaired responses in NIRKO mice are 
unique to hypoglycemia.  Further, the mechanism of insulin action in the brain must still 
be clarified.  In this study, experiments were conducted to determine whether the NIRKO 
model system exhibits a generalized (not hypoglycemia-specific) defect in the autonomic 
nervous system (ANS) mediated stress response.  It was found that NIRKO mice 
displayed normal physiological responses to various generalized stressors (i.e. restraint, 
heat, and cellular glucopenia) comparable to littermate controls.  To decipher a 
mechanism of CNS insulin action and glucose sensing, key glucose sensing proteins, 
including glucose transporters (GLUTs) and glucokinase (GK), were analyzed and 
measured. These glucose sensors were highly enriched in the ventromedial hypothalamus 
(VMH) and arcuate nucleus (ARC) of both NIRKO and control mice.  GLUT1 and 
GLUT3 protein and glucokinase mRNA and protein expression levels were not 
significantly altered in NIRKO mice.  Interestingly, expression of the insulin-responsive 
glucose transporter, GLUT4, within the ARC and VMH of NIRKO mice was found to be 
only 68% of control mice (p<0.05).  In summary, lack of insulin signaling in the brain led 
to a hypoglycemia-specific impairment in the sympathoadrenal response to hypoglycemia 
noted in this model.  Further, absent brain insulin action resulted in marked changes in 
glucose transporter expression, specifically GLUT4, which may account for the 
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previously noted glucose sensing impairment unique to this mouse model.  Therefore, we 
conclude that insulin acts in the brain to regulate GLUT4 expression in critically 
important sites within the hypothalamus necessary for normal brain glucose sensing and 
the normal sympathoadrenal response to hypoglycemia.   
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INTRODUCTION 
Insulin signaling is involved in many cellular processes, causing diverse effects on 
metabolism, longevity, and stress responses in various model systems (120).  Insulin’s 
actions also extend to the central nervous system where insulin can directly regulate food 
intake, body weight, and glucose homeostasis (24-31).  As seen in the NIRKO model, 
chronic lack of brain insulin signaling results in an impaired sympathoadrenal response to 
hypoglycemia (41).  Due to insulin’s ability to diversely effect disparate processes as well 
as cross the blood-brain barrier to directly activate the autonomic nervous system (34-
38), it is unclear whether the hypoglycemia impairment found in NIRKO mice is specific 
to altered glucose sensing or due to a generalized defect in its ability to respond to 
stressful insults.   
 
Insulin’s specific role in regulating CNS glucose sensing is ill-defined but growing 
evidence supports the hypothalamus (specifically the ventromedial hypothalamus) as the 
key glucose sensor that coordinates and triggers hypoglycemic counterregulation (8-11).  
Insulin receptors are highly expressed throughout the CNS, with specific enrichment in 
hypothalamic regions posited to be critical for regulating glucose homeostasis (19-23).  
As a result, insulin may play a predominate role in regulating CNS glucose sensing via 
glucose sensing neurons located in the ventromedial hypothalamus (VMH) 
(50;57;95;121;122).  These glucose sensing neurons share metabolic similarities to other 
well-characterized glucose sensing cells (i.e. pancreatic β-cells), especially with regards 
to glucose transport and metabolism (44;52;53).  Based on the expression of insulin 
receptors in the majority of glucosensing neurons in the VMH (68), it is postulated that 
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brain insulin action may mediate its effects on central glucose sensing by regulating 
expression of glucose transporters (GLUTs) and/or glucokinase (GK).  Several members 
of the glucose transporter family are expressed throughout the CNS (123).  GLUT1 and 
GLUT3 are the most abundant isoforms expressed in the brain (63;124-126), whose 
functions are thought to maintain basal brain glucose uptake.  GLUT4, the insulin 
responsive glucose transporter, is co-expressed with the insulin receptor in several 
hypothalamic regions (68) and is down-regulated under diabetic conditions (127).  
Subsequent to glucose transport, it may be that the enzyme glucokinase, a key regulator 
of glucose phosphorylation and metabolism in the β-cell and liver, may mediate insulin’s 
effects on glucose sensing in the hypothalamus (44;55).  Similar to insulin receptors, 
glucokinase is highly expressed in hypothalamic neurons (44;55;65;66;70;128).  Because 
insulin signaling regulates glucokinase expression and glucose sensing in liver and β-
cells (129;130), it is thought that insulin signaling may similarly regulate glucokinase 
expression and glucose sensing in the hypothalamus.  In this study, the NIRKO mouse 
model was utilized to assess insulin’s role in modulating the stress response to low 
glucose relative to other stressors.  Also, the potential mechanism of CNS insulin action 
was examined by evaluating alterations in key glucose sensing proteins that colocalize 
with insulin receptors, specifically GLUTs and GK. 
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MATERIALS AND METHODS 
Animals.  Mice homozygous for the floxed insulin receptor allele (IRlox-lox) were bred 
with transgenic mice that express Cre recombinase cDNA from the rat nestin promoter to 
generate (IRlox-lox:nestin-Cre+/-) nervous system specific insulin receptor knockout 
(NIRKO) mice (28). Genotypes were determined by PCR of tail DNA.  Unless otherwise 
indicated, 2-4 month old NIRKO and littermate control (Control, IRlox-lox:nestin-Cre-/-) 
mice were used for these experiments.  All mice were housed on a 12-hour light/dark 
cycle and fed a standard rodent chow (Mouse Diet 9F, PMI Nutrition International, St. 
Louis, MO) ad libitum.  All procedures were in accordance with the Guide for the Care 
and Use of Laboratory Animals of the National Institutes of Health and were approved by 
the Animal Studies Committee of Washington University. 
 
Brain Glucose Uptake.  Briefly, awake, unrestrained, cannulated NIRKO and littermate 
control mice (n=6-9 per group) underwent a 2-hour hyperinsulinemic (40mU/kg/min) 
hypoglycemic (30mg/dL) clamp protocol.  At 45 minutes prior to the end of the clamp, a 
5µCi bolus of 14C 2-deoxyglucose was rapidly infused intravenously and ten-timed (0, 
0.5, 2, 3, 5, 10, 15, 20, 30, and 45 min) arterial blood samples (10µL) were collected for 
analysis of arterial plasma glucose and 14C levels.  Immediately after the conclusion of 
the clamp, animals were euthanized and brains were rapidly harvested and quickly frozen 
in a dry ice and 2-methylbutane (Fisher, Saint Louis, MO) bath (-20o C).  Plasma 2-14C-
DG concentrations were determined by a dual-channel scintillation counter (Tri-Carb 
2800TR, PerkinElmer, Waltham, MA). Isotope concentrations in regions of interest, 
including the CA1, CA3, and dentate gyrus (DG) of the hippocampus, arcuate nucleus 
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(ARC), paraventricular nucleus (PVN), and ventromedial nucleus (VMH) of the 
hypothalamus, and nucleus of the solitary tract (NTS), were measured from 20µm thick 
coronal serial sections collected on heated coverslips at 60µm intervals.  Following, 
sections were exposed to autoradiograph film along with precalibrated 14C standards for 
2-4 days and analyzed via optical densitometry (ARC 146E, American Radiolabeled 
Chemicals, Inc., St. Louis, MO).  Regional glucose uptake was calculated according to 
Sokoloff’s equation utilizing rat rate constants, as mice rate constants have not been 
established (131).  
 
Restraint Stress.  Awake, 5-hour fasted, control and NIRKO mice (n=6 per group) were 
placed in a mouse restrainer (Braintree Scientific, Braintree, MA) for 45 minutes to 
induce restraint stress.  Cardiovascular parameters were obtained during the basal period 
and during the last 20 minutes of restraint stress using a tail-cuff system (Kent Scientific 
Corporation, Torrington, CT).  Blood samples (50µL) were taken by previously 
implanted arterial cannula at the beginning and end of the restraint period to measure 
plasma epinephrine levels. 
 
Heat Stress. Awake control and NIRKO mice (n=6 per group) were exposed to an 
ambient temperature of 42°C for 90 minutes to induce heat stress.  Blood samples were 
taken at the end of the heat stress period to measure catecholamines (50µL).  
Subsequently, cryoprotected brains were analyzed for heat stress induced c-fos 
immunostaining, as described in the immunohistochemistry methods section. 
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Systemic 2-deoxyglucose induced glucopenia.  In awake, 5-hour fasted, control and 
NIRKO mice, a single bolus of 2-deoxyglucose (600mg/kg IV, Sigma, St. Louis, MO) 
was given to induce glucopenic stress.  Blood samples (100µL) were taken by a 
previously implanted arterial cannula at the beginning and end of the stress period to 
measure plasma catecholamines and corticosterone levels. 
 
Central 2-deoxyglucose induced glucopenia.  Two weeks prior to the study, the animals 
were anesthetized with ketamine/xylazine (87 and 13.4mg/kg IP), and microinjection 
cannula (Plastics One Inc., Roanoke, VA) were inserted into the third ventricle.  For 
intracerebroventricular (ICV) injections, a solitary ICV cannula was inserted 1.6mm 
posterior to bregma, on the suture line, to a targeted depth of 5.5mm.  After a 5-7 day 
recovery, mice were anesthetized isofluorane and were implanted with catheters (MRE 
025, Braintree Scientific Inc., Braintree, MA) into the femoral artery.  The animals were 
then allowed approximately 4-7 days to recover prior to the experiment.  Simultaneously 
during the recovery period, mice were handled daily and the ICV cannula was tested to 
minimize stress the day of the experiment.   
 
One the day of the experiment, awake, unrestrained animals were rested 2 hours 
following exteriorizing the vessel cannula.  A basal blood sample (50µL) was taken at 
time 0 to measure basal catecholamine levels.  Following, the animals were gently, yet 
quickly immobilized to give a single infusion of 2-deoxyglucose (1mg/mouse, Sigma, St. 
Louis, MO) or a control artificial cerebrospinal fluid (aCSF) solution and returned to their 
home cages.  Blood glucose levels were monitored continuously throughout the 
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experiment.  At 45 minutes after injection, another blood sample was taken to measure 
catecholamine levels.  Animals were sacrificed at 120 minutes and the brains were 
cryoprotected for future c-fos analysis.  Animals were excluded from analysis if the ICV 
cannula was not positioned properly as determined on posthumous examination by track 
formation and evidence of Evans blue dye (0.01%). 
 
Immunohistochemistry.  Mice anesthetized with isofluorane and transcardially perfused 
with 0.01 M PBS (Sigma, Saint Louis, MO) followed by 4% paraformaldehyde (Electron 
Microscopy Sciences, Hatfield, PA).  The brains were immersed in 4% paraformaldehyde 
overnight and then cryoprotected in 30% sucrose.  Free-floating brain sections (20µm) 
were blocked with 30% normal goat serum diluted in 0.1% Triton-100/PBS and then 
incubated overnight at 4°C with c-fos antibody (1:2000, Ab-5, Calbiochem, San Diego, 
CA) or GLUT4 antibody (1:1000, generously gifted by Dr. M. Mueckler, Washington 
University in St. Louis). Subsequently, the sections were mounted on slides and 
processed with biotinylated goat anti-rabbit immunoglobulin G (1:200) using the Elite 
ABC kit (Vector Laboratories, Burlingame, CA). As a negative control, alternative 
sections were incubated without primary antibodies.  Regions of interest were identified 
using anatomical landmarks to identify the paraventricular nucleus (PVN), arcuate 
nucleus (ARC), or ventromedial nucleus (VMH) of the hypothalamus (100).  Positively 
stained cells were counted by a blinded investigator.  Four to six anatomically matched 
sections per mouse were quantified for statistical purposes. 
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Western Blots. The medial basal hypothalamus, defined anatomically as posterior to the 
optic chiasm, anterior to the mammillary body, inferior to the thalamus, and ±1mm lateral 
to the midline was dissected and frozen for analysis.  Samples were homogenized in 
buffer containing 1% Igepal (Sigma, Saint Louis, MO), 0.5%  Sodium Dodecyl Sulfate 
(SDS) (Sigma, Saint Louis, MO), 0.1 mM Phenylmethylsulfonyl Fluoride (PMSF) 
(Sigma, Saint Louis, MO), 1X complete protease inhibitor (Sigma, Saint Louis, MO), 1 
mM Sodium Fluoride (NaF) (Sigma, Saint Louis, MO), and 1 mM Sodium 
Orthovanadate (Na3VO4) (Sigma, Saint Louis, MO) in phosphate buffered saline 
(pH=7.4), centrifuged at 14,000 rpm for 30 minutes, and supernatant was collected. 
Homogenized hypothalamic protein extracts (20µg for GLUT1 and GLUT3; 100µg for 
GLUT4 and glucokinase) were fractionated by electrophoresis on a 10% Bis-Tris 
Criterion XT (Biorad, Hercules, CA) gel and subjected to transfer onto a nitrocellulose 
membrane (Biorad, Hercules, CA).  Following, the membranes were immunoblotted 
against the following primary antibodies: GLUT1 (1:5000, Chemicon, Temecula, CA), 
GLUT3 (1:1000, Chemicon, Temecula, CA), GLUT4 (1:1000, kindly supplied by Dr. M. 
Mueckler, Washington University in St. Louis, St. Louis, MO), Glucokinase (1:1000, 
Calbiochem, San Diego, CA).  The blots were developed using a horseradish peroxidase-
conjugated secondary antibody (1:8000, Cell Signaling, Boston, MA).  Primary antibody 
binding was detected by enhanced chemiluminescence ECL reagents (Perkin Elmer, 
Wellesley, MA) on ISO-MAX films and quantified by ImageQuant software analysis 
(Amersham Pharmacia, Piscataway, NJ).  An antibody against β-actin (1:2000, Sigma, 
St. Louis, MO) served as a loading control. 
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Immunofluorescence.  Mice anesthetized with isofluorane and transcardially perfused 
with 0.01 M PBS (Sigma, Saint Louis, MO) followed by 4% paraformaldehyde (Electron 
Microscopy Sciences, Hatfield, PA).  The brains were immersed in 4% paraformaldehyde 
overnight and then cryoprotected in 30% sucrose.  Briefly, free-floating hypothalamic 
sections (20-30µm) throughout the VMH/ARC were taken from 1.46 to 1.82mm caudal 
to bregma, blocked, and incubated overnight at 4°C in the GLUT4 primary antibody 
(1:1000).  Goat anti-rabbit Texas Red (1:200, Molecular Probes) was used as the 
secondary antibody.  Subsequently, the sections were mounted on slides using 
Vectashield Mounting Medium (Vector Laboratories, Burlingame, CA).  As a negative 
control, alternative sections were incubated without primary antibodies.  Regions of 
interest were identified using anatomical landmarks (100) and positively stained cells 
were counted by a blinded investigator.  Four to six brain sections per mouse were 
quantified for statistical purposes. 
 
RT-PCR.  Sections (400µm) were taken from brain sections 1.46 to 1.86mm caudal to 
bregma.  0.5mm bilateral punch biopsies from the VMH and ARC (0.75mm from the 
piriform cortex) were collected from NIRKO mice and littermate controls (n=7-8 per 
group).  The mRNA extracted with Trizol (Invitrogen Corporation, Carlsbad, CA) was 
subject to quantitative two-step RT-PCR reaction performed in triplicate in a fluorescent 
temperature cycler (GeneAmp 7700 Sequence Detector, Applied Biosystems) with 
glucokinase primers (glucokinase probe  5’ -/56-FAM/ACC GCC AAT GTG AGG TCG 
GCA /3BHQ_1/-3’; glucokinase reverse 5’- AGC CGG TGC CCA CAA TC- 3’; and 
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glucokinase forward 5’- CCA CAA TGA TCT CCT GCT ACT ATG A-3’).  The results 
were quantified after normalizing to ribosomal RNA L32mRNA. 
 
Statistics.  All values are presented as the mean ± standard error of the mean (SEM).  
Single comparisons between parameters were tested for statistical significance using a 
Student’s t test. For multiple group comparisons, statistical significance was determined 
by analysis of variance (ANOVA) using repeated measures followed by a Bonferroni 
post-hoc test to assess differences between experimental groups.  Statistical significance 
was set at p<0.05.   
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RESULTS 
Absent CNS Insulin Signaling does not Influence Response to Restraint or Heat Stress 
It is noted that NIRKO mice have an impaired response to hypoglycemia. Since the 
efferent response to stress involves common hypothalamic projections to spinal and 
medullary autonomic centers resulting in adrenomedullary activation (132), it was 
important to test the adrenomedullary response to other forms of stress in order to 
determine whether the impaired stress response in NIRKO mice was unique to 
hypoglycemia or part of a more generalized defect in the autonomic nervous system 
mediated stress (i.e., fight or flight) response unique to this knockout mouse.  NIRKO 
and control mice were subjected to two, glycemia-independent, stressors—a mild stressor 
(restraint stress) and a more profound stressor (heat stress)—in order to evaluate 
sympathoadrenal activation in response to glycemia-independent stress.  In response to 
milder restraint stress, plasma epinephrine levels were somewhat elevated in the basal 
state due to animal handling but rose similarly 2-fold in both littermate controls and 
NIRKO mice from this baseline during stress.  The physiological increased heart rate to 
restraint stress was also similar in control and NIRKO mice (Figure 12).  Heat stress 
induced a more pronounced catecholamine elevation than restraint stress (to levels within 
the range observed during hypoglycemia experiments), but the rise in both epinephrine 
and norepinephrine in response to heat stress was again not significantly different 
between groups (Figure 13).   
 
To determine whether the impairment in neuronal activation seen in NIRKO mice was 
unique to hypoglycemia, c-fos expression was also assessed in response to heat stress.  
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Increased c-fos expression was noted in the paraventicular nucleus (PVN) in response to 
heat stress (Figure 14), to levels observed with severe hypoglycemia (Figure 8); however, 
in response to heat stress, there was no difference in c-fos expression between groups 
(Control: 123±4 vs. NIRKO: 129±10, p=NS).   
 
Absent CNS Insulin Action does not Impair Physiological Responses to Systemic nor 
Central Cellular Glucopenia 
To ascertain whether the impaired counterregulatory response seen in NIRKO mice is 
due solely to insulin-induced hypoglycemia, an alternate glucopenic stimulus was 
utilized.  2-deoxyglucose (2-DG) is a commonly used agent thought to pharmacologically 
simulate hypoglycemia in animals.  2-DG is a non-metabolized glucose analog that 
deprives cells of metabolizable glucose, thus inducing a glucoprivic signal that triggers a 
counterregulatory response even in the presence of normal systemic glucose 
concentrations.  Other groups have demonstrated that administration of 2-DG can induce 
a profound counterregulatory response in animals, as well as induce neuronal activation 
within key glucose sensing regions of the hypothalamus (133;134).  When given 
systemically, 2-deoxyglucose increased blood glucose levels in both NIRKO and control 
mice (Figure 15).  There was also robust stimulation of epinephrine release, similar to 
levels induced by insulin-induced hypoglycemia, by NIRKO and control mice.  However, 
the rise in epinephrine seen in NIRKO mice was not different from that of controls 
(Figure 16).   Norepinephrine levels were not significantly elevated from baseline levels 
in either NIRKO mice or littermate controls in response to 2-DG (Figure 16).  Basal 
corticosterone levels were lower in NIRKO mice and the incremental response (i.e. delta) 
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induced by 2-DG stress was significantly greater in NIRKO mice vs. control mice; 
however, peak corticosterone levels during 2-DG stress were comparable to those seen in 
control mice (Figure 15). 
  
Subsequent experiments were performed to determine whether the counterregulation 
impairment seen in NIRKO mice was centrally-mediated.  2-DG was specifically 
administered to the 3rd ventricle of the hypothalamus to cause a localized glucoprivic 
insult.  In response to central 2-DG, NIRKO and control mice showed a matched rise in 
blood glucose (Figure 17).  Norepinephrine was not significantly elevated in either 
NIRKO or control mice in response to central 2-DG administration (Figure 17).  The 
norepinephrine response seen in NIRKO mice was comparable to littermate controls.  
Similarly, epinephrine levels trended higher due to 2-DG stress in both control and 
NIRKO mice, but the rise was not significant (Control: p=0.09 vs. CSF, NIRKO:  p=0.06 
vs. CSF) (Figure 17).   
 
Expression of Hypothalamic Glucose Sensors in Model of Abrogated Insulin Action 
To assess whether CNS insulin action regulates key glucose sensors, including 
glucokinase (GK) and glucose transporters (GLUTs), in the brain, hypothalamic protein 
and mRNA expression was assessed.  GK protein levels in the hypothalamus were 
comparable in control and NIRKO mice (Figure 18).  GK mRNA expression was 
preferentially expressed in the VMH and arcuate nucleus, but there was no difference in 
expression levels between experimental groups (Figure 18), consistent with the 
glucokinase protein expression findings.  Hypothalamic protein expression of GLUT1 
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and GLUT3 were 3-fold higher than hypothalamic protein expression of GLUT4.  
Relative to controls, GLUT1 protein levels in the hypothalamus were similar in NIRKO 
mice (Figure 19).  Hypothalamic GLUT3 protein levels in NIRKO mice were slightly 
(80.5±9.8% of control), but not significantly (p=0.08) reduced (Figure 19).  Interestingly, 
insulin-regulated GLUT4 protein levels were significantly reduced (68.5±5.5% of 
control, p<0.05) in the hypothalamus of NIRKO mice (Figure 19).  When assessing 
GLUT4 regional localization, immunohistochemistry results demonstrated that GLUT4 
protein was highly enriched in the ventromedial hypothalamus (VMH) and the arcuate 
nucleus (ARC) of control mice.  In NIRKO mice, GLUT4 protein expression was 
markedly reduced in these regions (Figure 20).  
 
Regional Brain Glucose Uptake during Hypoglycemia is not Altered in NIRKO Mice 
Based on the impaired glucose sensing and reduced GLUT4 expression found in NIRKO 
mice, it was postulated that glucose uptake might be altered in critical glucose sensing 
areas of NIRKO mice.  To measure regional specific brain glucose uptake, radiolabeled 
14C-2-deoxyglucose infusions during hyperinsulinemic-hypoglycemic clamps were used.  
In spite of reductions in glucose transporter expression in NIRKO mice, regional brain 
glucose uptake was not different between experimental groups within any areas assessed 
(Figure 21). 
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Figure 12. NIRKO mice have a normal physiological response to restraint stress. 
NIRKO (n=6, closed bars) and littermate control (n=6, open bars) mice were placed into 
a confining restraint device for 45 minutes. A&B. Plasma epinephrine levels (A) and 
heart rates (B) were elevated in response to restraint stress, but equally in control and 
NIRKO mice. (*p<0.05 vs. basal)  
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Figure 13. NIRKO mice display normal catecholamine responses to heat stress. 
NIRKO (n=6, closed bars) and littermate controls (n=6, open bars) were subjected to heat 
stress for 90 minutes.  Plasma epinephrine (top) and norepinephrine (bottom) levels were 
significantly stimulated by heat stress; however, there was no difference between NIRKO 
and control mice.  
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Figure 14. Normal neuronal activity in response to heat stress seen in NIRKO mice.  
NIRKO (n=6, closed bars) and littermate controls (n=6, open bars) were subjected to heat 
stress for 90 minutes. Top:  Representative images of matched hypothalamic sections 
highlighting heat stress induced c-fos staining in the paraventricular nucleus (PVN).  
Bottom:  Graph quantifying c-fos positive cells shows no difference between NIRKO 
and controls. 
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Figure 15.  NIRKO mice show normal physiological response to systemic glucopenic 
stress.  Top:  Blood glucose levels were similarly elevated in NIRKO (closed circles) 
and control (open circles) mice following 2-DG administration (as indicated by arrow).  
Bottom:  In NIRKO (closed bars) mice, basal corticosterone levels were slightly lower 
than controls (open bars).  As a result, the rise (i.e. delta) in corticosterone seen in 
NIRKO mice is significant; however, relative to controls, 2-DG stress induced 
corticosterone levels were not different between NIRKO and littermate control mice. 
(*p<0.05 vs. control) 
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Figure 16.  Catecholamine response to systemic glucopenic stress.  Top:  Epinephrine 
levels were significantly elevated in both NIRKO mice and littermate controls.  Bottom:  
Norepinephrine levels were slightly, but equally elevated by 2-DG stress in both NIRKO 
and control mice. (*p<0.05 vs. control) 
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Figure 17.   Central glucopenic stress induces modest physiological response in 
NIRKO mice.  Top:  Basal and peak blood glucose profile from NIRKO and 
control mice after 2-DG (closed bars) or aCSF (open bars) administration (n=4-7 mice 
per group).  Center:  Norepinephrine levels were similarly induced by 2-DG stress in 
NIRKO and littermate controls.  Bottom: Epinephrine levels trended higher in response 
to 2-DG; however, these responses were comparable between groups. (*p<0.05 vs. CSF)  
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Figure 18.  Glucokinase expression is not altered in NIRKO brains.  Top:  Western 
blots of whole hypothalamic extracts from NIRKO and littermate controls (n=5-6 mice 
per group). Graph quantifying protein expression (representative images below) is shown.  
Bottom: Although glucokinase mRNA was highly expressed in the ventromedial 
hypothalamus (VMH) and arcuate nucleus (ARC) as compared to the cortex, there was 
no difference between NIRKO (n=7, closed bars) and controls (n=8, open bars).  
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Figure 19.  Insulin-regulated glucose transporter 4, not GLUT1 or GLUT3, is 
reduced in NIRKO brains.  Western blots of whole hypothalamic extracts from NIRKO 
and littermate controls (n=5-6 mice per group) were performed. Representative images 
(top) and graph (bottom) quantifying protein expression of glucose transporters (GLUT1, 
GLUT3, and GLUT4) are shown. (**p<0.01 vs. control) 
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Figure 20.  GLUT4 expression is specifically reduced in key glucose sensing regions 
of the hypothalamus in NIRKO mice.  Regional localization of GLUT4 protein content, 
as determined by hypothalamic DAB staining (left) and immunofluorescence (right) of 
control (above) and NIRKO (below) mice, show enriched GLUT4 protein content in the 
ventromedial hypothalamus (VMH, circled) and arcuate nucleus (triangle) of control 
mice. GLUT4 protein content was 62±6% lower in NIRKO mice.  
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Figure 21.  Glucose uptake during hypoglycemia is preserved in the NIRKO brain. 
Regional brain glucose uptake was quantified using 14C 2-deoxyglucose during a 
hyperinsulinemic hypoglycemic (~30mg/dL) clamp.  Results show that regional brain 
glucose uptake in all regions measured [hippocampus (CA1, CA3, DG), hypothalamus 
(VMH, ARC, PVN), and hindbrain (NTS)] are similar among NIRKO (n=6, closed bars) 
and control mice (n=9, open bars). 
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DISCUSSION 
In this study, it was determined that lack of insulin receptor signaling in the central 
nervous system does not restrict the sympathoadrenal response to various glycemia-
independent stressors, but specifically alters glucose sensing in response to insulin-
induced hypoglycemia and alters the expression of a key glucose sensor, GLUT4, in the 
brain.  These findings indicate that insulin acts in the brain to uniquely regulate CNS 
glucose sensing and the sympathoadrenal response to hypoglycemia. 
 
Since the adrenomedullary response to hypoglycemia was not impaired during mild 
hypoglycemia in NIRKO mice, it was speculated that mild (restraint) stress, as noted by 
modest elevations in epinephrine levels (Figure 12), might not have been of sufficient 
magnitude to detect a differential response between control and NIRKO mice.  However, 
by achieving comparable epinephrine levels during severe stress (heat) and severe 
hypoglycemia (30mg/dL) and finding a normal catecholamine response to heat stress in 
NIRKO mice, these findings indicate that absent CNS insulin signaling does not impair 
the normal adrenomedullary response even to severe non-hypoglycemic stress (Figures 9 
and 13).  
 
Further, in response to a non-hypoglycemic stressor, heat stress increased c-fos 
expression to a similar magnitude as observed during severe hypoglycemia (30mg/dL); 
however, no difference in heat-induced c-fos expression was noted between control and 
NIRKO mice (Figure 14).  These results indicate that NIRKO mice have an intact 
neuronal circuitry for sensing and responding to non-hypoglycemic stress; therefore, the 
54 
 
impaired responses to hypoglycemia in the NIRKO mice appear to be unique to 
hypoglycemic stress and/or glucose sensing. 
 
2-deoxyglucose (2-DG) is a commonly used agent as it is thought to serve as an insulin-
independent, pharmacologically-induced hypoglycemia mimetic. Similar to glucose, 2-
DG is transported into cells via facilitative glucose transporters and phosphorylated via 
hexokinases.  However, because 2-DG lacks a hydroxyl group, it is not recognized by 
fructose isomerase and cannot be converted to fructose-6-phosphate, thus inhibiting its 
ability to undergo further glycolysis.  Furthermore, 2-DG effectively titrates away key 
glycolytic machinery, especially hexokinases, needed for normal glucose metabolism, in 
effect, ceasing glycolysis and causing a cellular starvation signal even in the presence of 
glucose abundance. 
 
Because 2-DG causes a cell to sense low glucose, it has been considered analogous to 
hypoglycemia for many experimental designs.  Unfortunately, the inability to accurately 
equate a dose of 2-DG to a corresponding degree of hypoglycemia precludes our ability 
to directly compare these two stressors.  In several studies, 2-DG has been used as a 
hypoglycemia surrogate in rat and mouse models of impaired counterregulation 
(58;75;135-139).  Data from these model systems predominately observed impairments 
of the counterregulatory glucagon response.  Of note, several studies (particularly mouse 
studies) failed to report if defects extended to other components of glucose 
counterregulation, namely catecholamine responses (58;75;137).  In this study, we found 
2-DG to stimulate the adrenomedullary response in NIRKO mice similarly to controls, 
55 
 
whether given systemically or centrally (Figures 16 and 17).  As we observed a 
prominent adrenomedullary impairment resulting from insulin-induced hypoglycemia in 
the NIRKO model, these results suggest that 2-DG is not an equivalent stressor as 
insulin-induced hypoglycemia in our model.  It is possible, due to the nature of the agent, 
2-DG may have directly activated downstream glucose sensors to normalize the 
counterregulatory response in NIRKO mice.  For example, the activity of nutrient sensor, 
AMPK, is increased by 30-50% in key hypothalamic regions of rats treated with 2-DG 
(137).  Since AMPK is an important modulator of hypoglycemic counterregulation and 
its activity is associated with augmented counterregulatory responses (81;83;137;140), it 
is plausible to speculate that 2-DG restored the counterregulatory defect in NIRKO mice 
by targeting AMPK or other downstream glucose sensors.  However, additional studies 
are required to address the specific mechanism of action. 
 
Similar to its well-characterized actions in muscle and fat, insulin-mediated GLUT4 
translocation has been demonstrated in neuronal cell lines (141), hippocampus (142), and 
hypothalamus (143).  This translocation to the plasma membrane is decreased in the 
brains of insulin resistant rats (142;143).  GLUT4 mediated glucose sensing has been 
speculated to be important at low glucose concentrations, where insulin-mediated glucose 
transport may act to supplement low intracellular glucose levels in hypothalamic glucose 
sensing neurons (57;122).  Indeed, supporting a glucosensing role for insulin receptors 
and GLUT4 is their coexpression in up to 75% of glucose responsive neurons in the 
VMH (68).  Further, neuronal GLUT4 has recently been shown to be an important 
mediator of hypoglycemic counterregulation and glucose sensing, as noted in neuronal 
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GLUT4 knockout mice (144).  During hypoglycemia, when glucose transport becomes 
rate-limiting (145), it was speculated that decreased GLUT4 expression and/or deficient 
insulin action would result in reduced glucose uptake in critical glucose sensing regions 
of NIRKO mice.  This study, however, noted equal regional brain glucose uptake during 
the hyperinsulinemic-hypoglycemic clamp (Figure 21), indicating that neither deficient 
insulin signaling nor the reduced GLUT4 levels altered glucose uptake in these brain 
areas.  Since brain GLUT4 expression is much lower than other glucose transporters, it is 
likely that glucose uptake was primarily regulated by the (insulin-independent and) more 
abundant GLUT1 and GLUT3, thus masking any subtle effect caused by decreased 
GLUT4.  While regional brain glucose uptake was not altered in NIRKO mice, an effect 
of insulin signaling and/or GLUT4 availability on mediating glucose uptake in individual 
glucose sensing neurons cannot be ruled out. 
 
The enzyme glucokinase (GK) has also been implicated as a mediator of CNS glucose 
sensing.  GK expression has been demonstrated in hypothalamic neurons by in-situ 
hybridization and RT-PCR (70).  Further, studies have shown that modulation of 
hypothalamic GK activity can alter the counterregulatory response to hypoglycemia 
(55;71).  Since insulin signaling regulates GK expression and glucose sensing in liver and 
β-cells (129;130;146), we postulated that insulin may also regulate GK expression in the 
brain.  Similar to the β-cell (βIRKO) (129) and liver (LIRKO) (146) specific insulin 
receptor knockout models, we expected impaired hypoglycemic counterregulation and 
glucose sensing to correlate with decreased GK expression in NIRKO mice.  Our studies, 
however, found no changes in GK expression (Figure 18).  Although we cannot rule out 
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an effect of insulin on GK activity, based on normal hypothalamic mRNA and protein 
expression in NIRKO mice, insulin’s effect on glucose sensing likely lies downstream of 
the glucose phosphorylation step. 
 
In the absence of a change in hypothalamic glucose uptake or glucokinase expression, it 
may be that insulin acts on glucose sensing hypothalamic neurons (or glia) via 
downstream metabolic effectors that limit net glycogen breakdown (147), inhibit AMPK 
(82), increase glycolysis and change NADH levels (50;51), modify ATP/ADP ratio 
(52;121;148;149), or insulin may directly regulate ATP-activated Cl- channel 
(101;119;150) or KATP channel activity (121;151;152) through actions of 3’-
phospholipids (153;154).   
 
In summary, it is shown that the chronic lack of insulin receptor signaling in the central 
nervous system decreases hypothalamic glucose transporter 4 expression, which may 
mediate insulin’s effects on CNS glucose sensing.  Further, the impaired 
sympathoadrenal response observed in NIRKO mice appears to be specific for glucose 
sensing, as the lack of CNS insulin signaling does not restrict neuronal activation or the 
adrenomedullary response to other generalized stressors.  It is concluded that insulin acts 
directly in the brain to uniquely regulate CNS glucose sensing via GLUT4.  By 
identifying GLUT4 as a key mediator of CNS insulin action, we are closer to uncovering 
the full mechanism by which insulin regulates central nervous system glucose sensing.  
This knowledge will allow us to identify key therapeutic targets to improve consequences 
associated with insulin-induced hypoglycemia in patients with diabetes. 
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THESIS DISCUSSION 
Hypoglycemia continues to be a barrier in achieving glycemia control for patients with 
Type 1 and advanced Type 2 diabetes.  Impaired brain glucose sensing limits the 
appropriate sympathoadrenal counterregulatory response and contributes to 
hypoglycemia unawareness, thus increasing the frequency and severity of hypoglycemia 
for patients with diabetes.  Unraveling the biology of neuronal glucosensing, the 
experiments in this thesis demonstrated a key role of CNS insulin signaling in regulating 
hypoglycemic counterregulation and glucose sensing.  Further, we have highlighted the 
role of a key component mediating insulin’s central effects, GLUT4, which can serve as a 
likely therapeutic target for preventing hypoglycemia caused by intensive insulin therapy. 
 
Insulin Therapy 
Glycemic control is the primary goal of diabetes therapy.  Unfortunately, achieving near-
normal glucose levels is often complicated by high variability with traditional insulin 
treatments.  Determining appropriate doses, timing, and routes of insulin delivery, 
conventional glucose management poses an enormous challenge in achieving and 
maintaining stable glucose levels.  In light of evidence of insulin’s role in the brain to 
regulate glucose homeostasis, prescribing the right insulin therapy now adds an additional 
level of complexity to glycemic management.  With the development of novel insulin 
analogues (Glargine (Lantus), Detemir (Levemir), intra-nasal insulin, inhaled insulin, 
etc.), patients with diabetes are able to improve glycemic control while limiting 
additional risks associated with intensive therapy.  However, these analogues have 
different pharmacodynamic properties that could enhance or restrict insulin transport 
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across the blood-brain-barrier (BBB) and thus alter the extent of insulin action in the 
CNS.  Normally, circulating insulin crosses the BBB via a saturable transport mechanism 
(35).  Yet, certain insulin analogues can cross the BBB more easily than human insulin, 
thus enabling it to enhance insulin signaling in targeted brain regions and modulate the 
counterregulatory response to hypoglycemia.  For example, the long-acting acylated 
insulin analogue Determir may enhance CNS insulin signaling.  Due to the lipophilic 
nature of Detemir, it may more easily cross the BBB relative to human insulin.  In mice, 
detemir administration resulted in higher hypothalamic insulin signaling compared to 
human insulin (155).  Further, detemir treatment is associated with lower incidences of 
hypoglycemia, less weight gain, and higher degrees of symptom awareness during 
hypoglycemia (156;157), indicative of enhanced CNS insulin signaling.  Similarly, intra-
nasal insulin can bypass the BBB, directly targeting brain tissue (158;159).  Although it is 
a less common treatment, intra-nasal administration is associated with reduced bouts of 
hypoglycemia (160;161).  Given the importance of aggressive insulin therapy in 
achieving and maintaining intensive blood glucose control, the extent to which insulin 
analogues act in the CNS is an important factor to consider as patients and healthcare 
providers assess the role of insulin action in the brain in mediating glucose sensing and/or 
the counterregulatory response to hypoglycemia.  
 
CNS Insulin Action 
Insulin and insulin signaling have been widely studied in classic “insulin-sensitive” 
peripheral tissues (i.e. fat, muscle, liver) for decades; yet, only recently has insulin action 
garnered appreciation for its role in the brain.  Centrally, insulin signaling influences 
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divergent metabolic pathways.  Of particular interest, brain insulin action has a novel role 
in regulating glucose homeostasis.  Unlike its peripheral actions to suppress hepatic 
glucose outflow, CNS insulin action enhances glucose output under conditions of 
hypoglycemia.   This dichotomous role of insulin action protects the body against overt 
glucose fluctuations and the associated consequences of glycemic dysregulation.  In this 
study, we examined the role of CNS insulin action in regulating the counterregulatory 
response to hypoglycemia.  The CNS-specific insulin receptor knockout (NIRKO) mouse 
was a powerful model system to conduct these experiments as it allowed us to isolate and 
clarify insulin’s role in a targeted tissue.  This study informed us of insulin’s unique role 
in regulating the adrenomedullary response to hypoglycemia.  It also highlighted its 
involvement in CNS glucose sensing.  Further, it gave us clues as to the specific site(s) 
and mechanism of CNS insulin action.   
 
In particular, this study recognized the ventromedial hypothalamus (VMH) as a potential 
site of CNS insulin action.  Elegant studies performed by Borg and colleagues, among 
others, illustrated the role of the VMH in CNS glucose sensing and glucose homeostasis 
(11;48-50).  With its targeted enrichment of insulin receptors and high population of 
glucosensing neurons, the VMH was postulated to be the most likely site of CNS insulin 
action.  These studies revealed key impairments of glucose sensing in VMH neurons and 
a distinct reduction in the key glucose sensing protein GLUT4 of NIRKO mice.  Overall, 
these results suggest the VMH serves as a site of insulin action; however, modifications 
observed in other brain regions suggest that the VMH is not the sole site of CNS insulin 
action.   
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The paraventricular nucleus (PVN) of the hypothalamus may also be a key site of insulin 
action.  In this study, impaired c-fos activity was predominately observed in this region.  
The PVN is primarily thought of as an integrating center of neuronal inputs.  Receiving 
input signals from the VMH and sending projections to autonomic centers, the PVN main 
purpose may be to serve as a second-level hypoglycemic detector that propagates 
neuronal responses initiated within the VMH.  However, the PVN also contains a large 
subset of glucose sensing neurons and a demonstrated role in hypoglycemic 
counterregulation (114;162).  As a consequence, the PVN may also act as a distinct, 
primary site of hypoglycemic detection and a key site of CNS insulin action.  The pan-
neural insulin receptor knockout of the NIRKO model established the importance of 
insulin action in the brain; however, additional studies are needed to clearly and 
definitively isolate specific nuclei as primary site(s) of insulin action.  Some studies have 
created hypothalamic specific insulin receptor knockdown models (95;143;163) to 
pinpoint the CNS site of insulin action.  Similar to NIRKO mice, targeted reductions in 
hypothalamic insulin receptor expression resulted in hyperphagia, weight gain, and 
insulin resistance in rats (95;143;163).  These studies also noted a reduction of plasma 
membrane GLUT4 expression in the hypothalamus (143).  Nevertheless, additional 
studies are required to unequivocally locate the specific site of CNS insulin action.  
Taking advantage of these approaches or generating nuclei- or cell type-specific insulin 
receptor knockout models via other transgenic, viral, or pharmacological approaches, the 
primary site(s) of CNS insulin action in regulating glucose sensing and the hypoglycemic 
counterregulatory response can be determined. 
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Insulin and Glucose Sensing Neurons 
Although the focal point of CNS insulin signaling is yet to be defined, this report 
demonstrates a significant role of insulin in influencing a specialized neuronal population 
of glucose sensing neurons (GSN).  Stimulated by fluxes in ambient glucose 
concentrations, it is believed that GSNs evolved to protect the brain against 
pathophysiologic glucose fluctuations, especially bouts of hypoglycemia (164).  As a 
result, GSNs are considered the primary modulators of glucose sensing and glucose 
counterregulation in the brain.  This thesis demonstrated impaired glucose responsiveness 
of hypothalamic glucose-inhibited (GI) neurons in NIRKO mice.  As the primary 
function of GI neurons is believed to stimulate hypoglycemic counterregulation, this 
glucose sensing impairment correlated well with the impaired sympathoadrenal response 
to hypoglycemia noted in the NIRKO model.  Similar to GI neurons, in vitro studies have 
also indicated a role for insulin to act directly on the glucose-excited (GE) neurons as 
well.  Previous studies have shown insulin to increase action potential frequency of 
arcuate nucleus glucose-excited neurons under conditions of low glucose (42).  Other 
studies have shown insulin to hyperpolarize VMH glucose-excited neurons by opening 
ATP-sensitive K+ channels (72;121).  Although GE neurons are presumably quiescent 
during hypoglycemia, these studies suggest that insulin may also regulate the glucose 
responsiveness of GE neurons, subsequently to regulate the counterregulatory response to 
hypoglycemia.   
 
It is unclear which aspects of glucose counterregulation are affected by the different 
subsets of GSNs or if they play distinct roles in regulating the counterregulatory 
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response.  However, emerging evidence suggest that GSNs may have distinct functions to 
coordinate the full counterregulatory response to hypoglycemia.  Some studies attribute 
the sympathoadrenal response to GI neurons while the glucagon response to 
hypoglycemia may be primarily regulated by GE neurons (102;165;166).  Due to the 
discrete localization of glucose sensing neurons in the VMH and technical challenges 
involving in isolating glucose sensing neurons, glucose responsiveness of GE neurons 
were not analyzed in our NIRKO mice.  Since insulin can influence both GI and GE 
neurons, it is fair to speculate that, similar to GI neurons, some, if not all, parameters of 
glucose responsiveness would be impaired in NIRKO GE neurons.  Alternatively, due to 
the intact glucagon response evident in the NIRKO model, glucose sensing in GE 
neurons may be preserved.  In either case, evaluating glucose sensing in NIRKO GE 
neurons would further highlight the importance of CNS insulin action in central glucose 
sensing.  It could also uncover the interplay between the two types of glucose sensing 
neurons and how they might communicate to regulate glucose sensing and hypoglycemic 
counterregulation.   
 
CNS Insulin Action and Downstream Glucose Sensors 
Insulin receptor signaling is an elaborate signaling cascade that coordinates the 
activation/regulation of a number of downstream mediators to facilitate insulin’s effects 
on various metabolic processes.  In peripheral glucose sensing, the mechanism of 
insulin’s actions on various sensing proteins are well-defined.  Whether central insulin 
signaling mimics peripheral action is unclear; however, identification of shared and novel 
CNS insulin action mediators draws us closer to defining the mechanism of CNS insulin 
64 
 
action.  One major mediator of peripheral insulin action is the family of facilitative 
glucose transporters (GLUTs).  Predominately, GLUT4 is a primary target of peripheral 
insulin action.  This insulin-regulated transporter plays a key role in maintaining glucose 
homeostasis by enhancing insulin stimulated glucose uptake in peripheral tissues.    Due 
to colocalization with insulin receptor in key glucosensing areas, it was speculated that, 
similar to peripheral actions, insulin may regulate brain GLUT4 (68), such that impaired 
GLUT4 activity and/or expression might contribute to defective CNS glucose sensing 
observed in the NIRKO mouse.  Previous studies have shown that GLUT4 is localized to 
glucosensing regions of the hypothalamus and GLUT4 expression is down-regulated 
under diabetic conditions (127;142).  In this thesis, immunohistochemistry results 
indicated that GLUT4 protein expression was markedly decreased (to approximately 30% 
of controls) in the ventromedial hypothalamus (VMH) and arcuate nucleus (ARC) of 
NIRKO mice.  These results suggest that insulin acts in the brain to regulate glucose 
transporter expression in critical glucose sensing regions of the hypothalamus.  
Corroborating an important role of brain GLUT4, neuronal specific GLUT4 knockout 
mice also demonstrate impaired glucose sensing and hypoglycemic counterregulation 
(144).  
 
Glucokinase (GK) has also been shown to be important sensing protein in glucosensing 
neurons (55;68;75;167) and may also mediate insulin’s effects within the brain.  In this 
study, there were no changes in GK expression levels; however, activity was not assessed 
in this study.  Due to glucokinase’s demonstrated role in regulating hypoglycemic 
counterregulation, it is worthwhile to assess insulin’s direct effects on GK activity.  Other 
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potential glucose sensors that may mediate insulin’s central effects are ATP-sensitive ion 
channels and the fuel gauge AMPK.  Similar to GLUTs and GK, mounting evidence 
highlights the emerging roles of both ion channels and AMPK in mediating hypothalamic 
glucose sensing (74-76;81-83;168).  Spanswick and others found that insulin can regulate 
GE neuronal responsiveness via KATP activation (121;122).  In the periphery, the effects 
on insulin on AMPK activity have been variable.  In the heart, insulin inhibits AMPK 
(169;170) while reduced insulin signaling correlated to decreased AMPK activity in 
trophoblast stem cells (171).  There is also some evidence that insulin may regulate 
hypothalamic AMPK activity (82); however, the nature of insulin’s effects on 
hypothalamic AMPK activity must be further clarified.  By evaluating insulin’s effects on 
these downstream glucose sensors in further detail, a clear description of insulin’s 
mechanism of CNS action will develop. 
 
Summary 
On a quest to achieve near-normoglycemia, hypoglycemia and impaired glucoregulation 
are serious challenges faced by insulin-treated diabetic patients.  Insulin effects extend 
beyond classic insulin-sensitive tissues to include major influences in the brain to 
regulate glucose homeostasis, central nervous system (CNS) glucose sensing, and the 
counterregulatory response to hypoglycemia.  The experiments in this thesis investigated 
insulin’s role in regulating hypothalamic glucose sensing and the counterregulatory 
response to hypoglycemia.  Utilizing a genetic mouse model which chronically lacks 
CNS insulin action (NIRKO mouse), this report demonstrated CNS insulin action to 
regulate the glucose sensitivity of glucose sensing neurons in the VMH.  This report also 
showed CNS insulin action to uniquely modulate hypothalamic neuronal activation and 
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the sympathoadrenal response to hypoglycemic stress, not other stressors.  Finally, it was 
found that insulin action in the brain regulates GLUT4 expression, which may operate as 
the primary mediator of CNS insulin action.  Results of this study provided novel insights 
into insulin’s role in regulating CNS glucose sensing and the counterregulatory response 
to hypoglycemia.  This insight can aid in the overall understanding as to how the brain 
regulates the counterregulatory response to hypoglycemia in order to devise therapies to 
combat severe hypoglycemia. 
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